Turn An Excel Sheet Into An Interactive Dashboard Using Python (Streamlit)
how to build interactive Excel dashboards with Python using the Streamlit library. Streamlit allows us to create interactive Dashboards with a few lines of code. We will start by installing the necessary Python libraries. Afterwards, we will dive into building an interactive dashboard with Streamlit, which will be easy to customize and provide excellent user interaction.
https://t.co/2ZHGhdoMQY
Nvidia CEO Jensen talked about the first time ever that Elon Musk asked for his chips
"When I announced this thing, nobody in the world wanted it. I had no purchase orders. Not, not one. Nobody wanted to buy it. Nobody wanted to be part of it, except for Elon." 🤝
AI just ran 80–90% of a state-backed cyber-espionage campaign.
Open-source tools, hijacked frontier models, 30+ Western targets.
Has the cyber cold war has gone AI-native — the next edge must be governance and defence at machine speed. #AIThreats#CyberWarfare#AIGeopolitics
China’s labs now power a third of global clinical trials.
Big pharma’s patent cliff is pulling Chinese drugs onto Western shelves.
The next wave of blockbuster medicines may be made in China – and regulated in Washington.
Alphabet hasn’t just rallied — it’s been re-rated.
Forward P/E surged from 16x→28x, a +74% jump in six months.
The market now treats GOOGL as a core AI platform, not a cyclical ad stock.
OpenAI still leads — but the threat perimeter is widening.
China’s open source, Meta’s Llama, Microsoft’s hedging, xAI, and orthogonal startups are reshaping the next frontier.
The real risk: AI becomes a commodity faster than expected.
Enterprise market is fragmenting faster than the consumer market. API share data suggests OpenAI’s enterprise share is falling from 48% (2023) to mid-20s by 2025, driven by Anthropic’s technical reliability, enterprise-grade safety stack, and deeper penetration into Fortune 500
OpenAI’s consumer dominance is intact but eroding at the margins. Similarweb’s traffic data shows OpenAI still holding the overwhelming majority of public-facing AI usage, but the share has declined from ~80% to the low-70s as alternatives expand rapidly
No More Animal Testing.
AI is redesigning the lab bench. Models like RFantibody generate antibodies from code—cutting costs and timelines.
The new biotech edge is algorithmic.
#AI#Biopharma#GenerativeAI
📖 FT | Nov 2025 – Univ. of Washington breakthrough
AI compute is growing exponentially—far faster than Moore’s Law ever predicted.
The real constraint is no longer silicon, but power, cooling, and capital.
#AI#Compute#MacroTrends#GlobalInsights